Literature DB >> 26349784

Authors' reply concerning the letter by Ensminger et al.

Michael Weis1, Gerhard Steinbeck2, Bruno Reichart2, Tassilo Hübner2, Thomas Nickel2, Steffen Massberg2, Rene Schramm2, Christian Hagl2, Axel Kiwi2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26349784     DOI： 10.1007/s00392-015-0908-2

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN： 1861-0684            Impact factor:   5.460


× No keyword cloud information.
  15 in total

Review 1.  Inotropic therapy for heart failure: an evidence-based approach.

Authors:  G M Felker; C M O'Connor
Journal:  Am Heart J       Date:  2001-09       Impact factor: 4.749

2.  Optimal pharmacologic and non-pharmacologic management of cardiac transplant candidates: approaches to be considered prior to transplant evaluation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006.

Authors:  Mariell Jessup; Nicholas Banner; Susan Brozena; Carlo Campana; Angelika Costard-Jäckle; Thomas Dengler; Sharon Hunt; Marco Metra; Axel Rahmel; Dale Renlund; Heather Ross; Lynne Warner Stevenson
Journal:  J Heart Lung Transplant       Date:  2006-09       Impact factor: 10.247

3.  Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure.

Authors:  Uri Elkayam; Gudaye Tasissa; Cynthia Binanay; Lynne W Stevenson; Mihai Gheorghiade; J Wayne Warnica; James B Young; Barry K Rayburn; Joseph G Rogers; Teresa DeMarco; Carl V Leier
Journal:  Am Heart J       Date:  2007-01       Impact factor: 4.749

4.  Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure.

Authors:  Michael J Bonios; John V Terrovitis; Stavros G Drakos; Fotis Katsaros; Chris Pantsios; Serafim N Nanas; John Kanakakis; George Alexopoulos; Savvas Toumanidis; Maria Anastasiou-Nana; John N Nanas
Journal:  Int J Cardiol       Date:  2011-04-08       Impact factor: 4.164

Review 5.  Intermittent positive inotrope infusion in the management of end-stage, low-output heart failure.

Authors:  B S Levine
Journal:  J Cardiovasc Nurs       Date:  2000-07       Impact factor: 2.083

6.  Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure.

Authors:  A Hatzizacharias; T Makris; P Krespi; F Triposkiadis; P Voyatzi; N Dalianis; M Kyriakidis
Journal:  Am Heart J       Date:  1999-08       Impact factor: 4.749

7.  Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.

Authors:  J T Parissis; S Adamopoulos; D Farmakis; G Filippatos; I Paraskevaidis; F Panou; E Iliodromitis; D Th Kremastinos
Journal:  Heart       Date:  2006-12       Impact factor: 5.994

8.  The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis.

Authors:  Simon Thackray; Joanne Easthaugh; Nick Freemantle; John G F Cleland
Journal:  Eur J Heart Fail       Date:  2002-08       Impact factor: 15.534

9.  Intermittent infusion of dobutamine in the therapy of severe congestive heart failure--long-term effects and lack of tolerance.

Authors:  H H Erlemeier; W Kupper; W Bleifeld
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

Review 10.  Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials.

Authors:  Simona Silvetti; Teresa Greco; Ambra Licia Di Prima; Marta Mucchetti; Castro Maria de Lurdes; Laura Pasin; Mara Scandroglio; Giovanni Landoni; Alberto Zangrillo
Journal:  Clin Res Cardiol       Date:  2013-12-25       Impact factor: 5.460
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.